Correlation of Glut-1 glucose transporter expression with [18F]FDG uptake in non-small cell lung cancer

• Published in: European Journal of Nuclear Medicine 2000-12, Vol.27 (12), p.1778-1785
• Main Authors: HIGASHI, Kotaro, UEDA, Yoshimichi, TONAMI, Hisao, KATSUDA, Shogo, YAMAMOTO, Itaru, SAKURAI, Aya, XIAO MING WANG, LINFENG XU, MURAKAMI, Manabu, SEKI, Hiroyasu, OGUCHI, Manabu, TAKI, Suzuka, NAMBU, Yoshihiro
• Format: Article
• Language: English
• Subjects: Biological and medical sciences; Investigative techniques, diagnostic techniques (general aspects); Medical sciences; Pneumology; Radionuclide investigations; Respiratory system; Tumors of the respiratory system and mediastinum
• ISSN: 0340-6997; 1619-7089
• DOI: 10.1007/s002590000367

Positron emission tomography (PET) with [(18)F]2-fluoro-2-deoxy-D-glucose (FDG) may show negative results for bronchioloalveolar lung carcinoma. We investigated the correlation of Glut-1 glucose transporter expression with [(18)F]FDG uptake in non-small cell lung cancer. Thirty-two patients with 34 non-small cell lung cancers (7 bronchioloalveolar carcinomas, 23 non-bronchioloalveolar adenocarcinomas, 3 squamous cell carcinomas, and 1 adenosquamous cell carcinoma) were studied. Final diagnoses were established by histology (via thoracotomy) in all patients. [(18)F]FDG PET was performed 40 min after i.v. injection of 185 MBq [(18)F]FDG. For semi-quantitative analysis of [(18)F]FDG uptake, standardized uptake values (SUVs) were calculated. Glut-1 expression was studied in terms of the immunohistochemistry of paraffin sections using anti-Glut-1 antibody to determine the intensity (0-3) of Glut-1 immunoreactivity and percentage of the Glut-1-positive area. Of seven bronchioloalveolar carcinomas, six (85.7%) were negative for the expression of Glut-1, while only one (4.3%) of 23 non-bronchioloalveolar adenocarcinomas was negative (P